Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LadRx CorpCYTR · Entity 94858 | EVP and Chief Medical Officer | December 15, 2016 | December 19, 2016 |
| Neurogene Inc.AQXP · Entity 5160 | Director | May 14, 2018 | May 16, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LadRx Corp
Report date December 15, 2016 · Filed December 19, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2026-12-14 | Direct | 400,000 |
Reported balance
After 2016-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-12-15 · Grant · Acquired 400,000 · Balance 400,000 F1: The stock option vests monthly for 36 months in equal installments, beginning 15 January 2017, provided Reporting Person remains in continuous employ of Issuer, or the conditions for immediate vesting do not occur. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests monthly for 36 months in equal installments, beginning 15 January 2017, provided Reporting Person remains in continuous employ of Issuer, or the conditions for immediate vesting do not occur.
Neurogene Inc.
Report date May 14, 2018 · Filed May 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-05-14 · Exercise / conversion · Acquired 3,906 · Balance 3,906 Row 2 · 2018-05-14 · Sale · Disposed 3,906 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.65 to $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2018-07-01 | Direct | 0 |
Reported balance
After 2018-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-14 · Exercise / conversion · Disposed 3,906 · Balance 0 F2: All the shares subject to the 3,906 share option were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.65 to $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote.
F2: All the shares subject to the 3,906 share option were fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2018 Filed May 16, 2018 23:45 UTC | Neurogene Inc. AQXP · Entity 5160 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,906 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-18-030711 · doc4.xml · derivative · entry 3 LEVITT DANIEL J · CIK 0001278711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,906 shares Expires 2018-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All the shares subject to the 3,906 share option were fully vested. Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:45 UTC | Neurogene Inc. AQXP · Entity 5160 | SaleCommon Stock | 3,906 | $12.67 | $49,489.02 |
DisclosureSEC source: 0001209191-18-030711 · doc4.xml · nonDerivative · entry 2 LEVITT DANIEL J · CIK 0001278711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.65 to $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set in this footnote. Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:45 UTC | Neurogene Inc. AQXP · Entity 5160 | Exercise / conversionCommon Stock | 3,906 | $10.56 | $41,247.36 |
DisclosureSEC source: 0001209191-18-030711 · doc4.xml · nonDerivative · entry 1 LEVITT DANIEL J · CIK 0001278711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:11 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001209191-18-028968 · doc4.xml · derivative · entry 1 LEVITT DANIEL J · CIK 0001278711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| May 08, 2017 Filed May 10, 2017 22:33 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $13.74 | $0.00 |
DisclosureSEC source: 0001209191-17-031397 · doc4.xml · derivative · entry 1 LEVITT DANIEL J · CIK 0001278711 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-05-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 14:32 UTC | LadRx Corp CYTR · Entity 94858 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001140361-16-090198 · doc1.xml · derivative · entry 1 LEVITT DANIEL J · CIK 0001278711 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: CytRx Common Stock · 400,000 shares Expires 2026-12-14 F1 · derivative.exercise_date: The stock option vests monthly for 36 months in equal installments, beginning 15 January 2017, provided Reporting Person remains in continuous employ of Issuer, or the conditions for immediate vesting do not occur. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.